Some well-known BET inhibitors include JQ1, OTX015 (MK-8628), and CPI-0610. JQ1, a pioneering BET inhibitor, has been extensively studied in preclinical models. OTX015 and CPI-0610 are currently in clinical trials and have shown potential in treating various cancers. These inhibitors differ in their pharmacokinetic properties and selectivity, which can influence their therapeutic efficacy and side-effect profiles.
